Pfizer Inc on Tuesday secured a reprieve from US President Donald Trump’s long-threatened tariffs on the pharmaceutical industry by agreeing to slash some of its drug prices by up to 85 percent and selling directly to the US public, a move other major drugmakers are expected to follow.
Pfizer said it would ensure Americans receive comparable prices to those offered in other countries and would launch new medicines at parity, addressing a key Trump complaint that Americans unfairly shoulder the highest medical costs in the world.
In exchange, the company gained a three-year grace period from widely anticipated pharmaceutical tariffs that the Trump administration has been promulgating.
Photo: AFP
It is the latest example of the transactional nature of winning tariff exemptions from Trump, who has unilaterally wielded trade policy to exert power over multiple industries. As recently as last week, he threatened 100 percent tariffs on the pharmaceutical industry.
Similar deals could be forthcoming. Eli Lilly & Co said it is in discussions with the Trump administration to further expand patient access, as the announcement on Tuesday underscores the urgency of making medicines more affordable.
The latest deal appears to resolve two major threats facing Pfizer. It averts more damaging pricing policies on medicines, while shielding the company from tariffs tied to the administration’s Section 232 investigation into whether drug costs represent a national security threat.
The deal is a boon for Pfizer chief executive officer Albert Bourla, who has struggled to replace flagging sales of COVID-19 vaccines and therapies that were in high demand during the pandemic. It also yielded rare praise from US health officials, who previously criticized the CEO and his company.
“Albert and I have had a long history of antipathy and antagonism toward each other,” US Secretary of Health Robert F. Kennedy Jr said. “But I have to say his leadership in this took tremendous courage, and he really created a template for corporate responsibility, for putting public health ahead of his individual interests.”
Pfizer is to offer a large majority of its primary care treatments and some specialty brands at discounts of up to 85 percent — and at an average of 50 percent off — on a direct-to-consumer Web site called TrumpRx. The initiative is intended to allow Americans to pay for prescriptions at discounted rates that are negotiated by the government.
Pfizer also plans a US$70 billion push on research and development, and domestic manufacturing over the next few years, Bourla said.
The company did not specify which of its medicines would be made available on TrumpRx, but said the majority of its primary care drugs would be offered on the site.
Pfizer’s top-selling drugs include the blood-thinner Eliquis, the pneumonia vaccine Prevnar, and a shot and pill for COVID-19.
Most pharmaceutical companies declined to comment on the Pfizer news or did not return inquiries seeking comment.
Merck & Co said it is committed to working with the administration, and supports rising foreign prices and lowering US prices. Novo Nordisk A/S said it engaged in discussions with the administration, and is focused on improving patient access and affordability.
After several years flying high as Asia’s best Nvidia Corp proxy, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is increasingly vying with other artificial intelligence (AI) stocks for investor attention. Stock traders are chasing a wider array of beneficiaries as mainstream usage of AI creates demand for hardware beyond the most-advanced chips TSMC makes for Nvidia. Subthemes from the deepening memory crunch to advances in robotics are also luring bids. At the same time, investment caps on single stocks are pushing funds to diversify, while retail investors long familiar with TSMC through its US depositary receipts are being offered a broader set of
UNDER MICROSCOPE: Taiwan detained three people who allegedly conspired to buy servers in Taiwan and export them using fraudulent documentation, prosecutors said Nvidia Corp chief executive officer Jensen Huang (黃仁勳) on Saturday urged Super Micro Computer Inc to tighten up on compliance after Taiwan detained three people this week for allegedly making fraudulent declarations about artificial intelligence (AI) servers made by its US partner. The development marked the nation’s first crackdown on semiconductor smuggling, which grew after the US slapped restrictions on exports of high-end chips such as Nvidia AI accelerators to China. Nvidia is “rigorous” in explaining regulations to all of its partners, Huang told reporters after arriving in Taipei. “Ultimately Super Micro has to run their own company,” he said in response to
TECH RELIANCE: Growth is increasingly reflecting an unequal K-shaped distribution, where technology sectors outperform and other industries struggle, an expert said Standard Chartered Bank has significantly raised its forecast for Taiwan’s economic growth to 9.5 percent this year, up from 7.6 percent previously, citing surging artificial intelligence (AI) demand driving exports, semiconductor production and investment. The upgrade reflects a sustained AI supercycle that continues to fuel demand for advanced chips and technology infrastructure, which form the backbone of Taiwan’s exports, the bank said in a report this week. “We raise our 2026 growth forecast to reflect a much stronger-than-expected first-quarter GDP figure,” Standard Chartered senior economist for greater China and Asia Tommy Wu (胡東安) said in the report. Driven largely by a 35.3 percent
Two of Taiwan’s international carriers, Starlux Airlines Co (星宇航空) and EVA Airways Corp (長榮航空), have retained the five-star airline rating awarded by international airline review organization Skytrax. Starlux was awarded the distinction for a second consecutive year, while EVA Air received it for the 11th straight year, Skytrax said in statements released yesterday and on Thursday last week, respectively. The five-star rating is considered one of the airline industry's highest honors and is awarded following professional audits of airline product and frontline service standards, Skytrax said. The ratings are based on in-depth assessments using unified global quality standards rather than customer review scores
RSS